# Retatrutide References: Cited Clinical Trial and Research Literature — Clinic Retatrutide

> Full citation list for the Retatrutide research record: Jastreboff NEJM 2023, Rosenstock Lancet 2023, Sanyal Nature Medicine 2024, TRIUMPH Phase 3 results, and all cited sources.

All sources cited across this Retatrutide reading desk, listed in citation order. PubMed links and DOIs are included where available. This site summarizes the peer-reviewed research literature; it does not conduct original research.

## References

[1] Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(8):2195-2204. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[4] Li et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10:76. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[5] Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results). Eli Lilly Investor Relations / PR Newswire. 2025. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
[6] Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/abstract
[7] Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. PMC / systematic review. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
[8] Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Eli Lilly Investor Relations. 2025. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
[9] Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. PubMed. 2024. https://pubmed.ncbi.nlm.nih.gov/39305981/
[10] Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
[11] Clinical Trials Arena / ESC Congress presentation. ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial. Clinical Trials Arena. 2024. https://www.clinicaltrialsarena.com/analyst-comment/esc-2024-retatrutide-lipid-cardiovascular-risk-profile-phase-ii/
[12] Pasqualotto E, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11420505/
[13] Belay KE, Jemal RH, Tuyizere A. Innovative Glucagon-based Therapies for Obesity. J Endocr Soc. 2024;8(12). https://pmc.ncbi.nlm.nih.gov/articles/PMC11579655/
[14] Lopes T, Hope DCD, Ramos-Pittol JM, et al. Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice. Mol Metab. 2024;89:102024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11424806/
[15] Alves GAM, Teranishi M, Ortega ACTCG, James F, Arachchige ASPM. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. Med Sci (Basel). 2025;13(3):136. https://pmc.ncbi.nlm.nih.gov/articles/PMC12372146/
[16] Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D. Triple Agonism Based Therapies for Obesity. Curr Cardiovasc Risk Rep. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/
[17] Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. PR Newswire. 2025. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
[18] Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap. PubMed. 2025. https://pubmed.ncbi.nlm.nih.gov/41909366/
[19] Ramsbacher N. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024;42(4):499-507. https://pmc.ncbi.nlm.nih.gov/articles/PMC11486854/
[20] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[21] Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[22] Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2025. https://pubmed.ncbi.nlm.nih.gov/40291085/

---

A peer-reviewed reading desk — not a clinic, not a vendor, not a source of medical guidance.